Piking the winners and shipping the new combos
In the second part of this mini-series on an important oncogenic target, we’re going to explore some topics around the theme of coalescence.
This means we can look at how do cancers hijack multiple pathways or co-opt critical cell growth related genes to help drive their own growth, proliferation, and survival.
If we understand the processes involved then we can start thinking about what we can do to interrupt or shut them down then develop relevant therapeutic strategies to tackle them.
Additionally, several targets have now been made druggable where they were considered intractable when this pathway axis was at its peak. This may offer some fresh opportunities for progress in ways which were not feasible before.
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers